| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Radiation and Cellular Oncology [D. H. G., M. A. B., D. P. C., H. J. M., S. S., A. K., D. M. H., R. R. W.] and Surgery [N. T. J., R. M. S.], University of Chicago, Chicago, Illinois 60637, and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115 [D. W. K.]
The family of vascular endothelial growth factor (VEGF) proteins include potent and specific mitogens for vascular endothelial cells that function in the regulation of angiogenesis. Inhibition of VEGF-induced angiogenesis, either by neutralizing antibodies or a dominant-negative soluble receptor, blocks the growth of primary and metastatic experimental tumors. Here we report that VEGF expression is induced in Lewis lung carcinomas (LLCs) both in vitro and in vivo after exposure to ionizing radiation (IR) and in human tumor cell lines (Seg-1 esophageal adenocarcinoma, SQ20B squamous cell carcinoma, T98 and U87 glioblastomas, and U1 melanoma) in vitro. The biological significance of IR-induced VEGF production is supported by our finding that treatment of tumor-bearing mice (LLC, Seg-1, SQ20B, and U87) with a neutralizing antibody to VEGF-165 before irradiation is associated with a greater than additive antitumor effect. In vitro, the addition of VEGF decreases IR-induced killing of human umbilical vein endothelial cells, and the anti-VEGF treatment potentiates IR-induced lethality of human umbilical vein endothelial cells. Neither recombinant VEGF protein nor neutralizing antibody to VEGF affects the radiosensitivity of tumor cells. These findings support a model in which induction of VEGF by IR contributes to the protection of tumor blood vessels from radiation-mediated cytotoxicity and thereby to tumor radioresistance.
This article has been cited by other articles:
![]() |
M. I. Koukourakis, A. Giatromanolaki, H. Sheldon, F. M. Buffa, G. Kouklakis, I. Ragoussis, E. Sivridis, A. L. Harris, and for the Tumour and Angiogenesis Research Group Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab Clin. Cancer Res., November 15, 2009; 15(22): 7069 - 7076. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Shannon, B. A. Telfer, P. D. Smith, M. Babur, A. Logie, R. W. Wilkinson, C. Debray, I. J. Stratford, K. J. Williams, and S. R. Wedge The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts Clin. Cancer Res., November 1, 2009; 15(21): 6619 - 6629. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Kim, L. Moretti, L. R. Mitchell, D. K. Jung, and B. Lu Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non-Small Cell Lung Tumor Xenograft Model Clin. Cancer Res., October 1, 2009; 15(19): 6096 - 6105. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Crane, K. Winter, W. F. Regine, H. Safran, T. A. Rich, W. Curran, R. A. Wolff, and C. G. Willett Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411 J. Clin. Oncol., September 1, 2009; 27(25): 4096 - 4102. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Chi, A. G. Sorensen, R. K. Jain, and T. T. Batchelor Angiogenesis as a Therapeutic Target in Malignant Gliomas Oncologist, June 1, 2009; 14(6): 621 - 636. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Moretti, K. W. Kim, D. K. Jung, C. D. Willey, and B. Lu Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor Mol. Cancer Ther., May 1, 2009; 8(5): 1270 - 1279. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schoder, M. Fury, N. Lee, and D. Kraus PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 74S - 88S. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Harada, S. Itasaka, S. Kizaka-Kondoh, K. Shibuya, A. Morinibu, K. Shinomiya, and M. Hiraoka The Akt/mTOR Pathway Assures the Synthesis of HIF-1{alpha} Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors J. Biol. Chem., February 20, 2009; 284(8): 5332 - 5342. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Y. Kim, S. H. Oh, J.-K. Woo, W. K. Hong, and H.-Y. Lee Targeting Heat Shock Protein 90 Overrides the Resistance of Lung Cancer Cells by Blocking Radiation-Induced Stabilization of Hypoxia-Inducible Factor-1{alpha} Cancer Res., February 15, 2009; 69(4): 1624 - 1632. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Birk, J. Barbato, L. Mureebe, and R. A. Chaer Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation Vascular and Endovascular Surgery, January 1, 2009; 42(6): 517 - 530. [Abstract] [PDF] |
||||
![]() |
K J Williams, B A Telfer, A M Shannon, M Babur, I J Stratford, and S R Wedge Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTINTM; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S21 - S27. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Danovi, H. H. Wong, and N. R. Lemoine Targeted therapies for pancreatic cancer Br. Med. Bull., September 1, 2008; 87(1): 97 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Chang, I. Rizvi, N. Solban, and T. Hasan In vivo Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment Clin. Cancer Res., July 1, 2008; 14(13): 4146 - 4153. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ning, J. A. Nemeth, R. L. Hanson, K. Forsythe, and S. J. Knox Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo Mol. Cancer Ther., June 1, 2008; 7(6): 1569 - 1578. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Y. Seiwert, D. J. Haraf, E. E.W. Cohen, K. Stenson, M. E. Witt, A. Dekker, M. Kocherginsky, R. R. Weichselbaum, H. X. Chen, and E. E. Vokes Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1732 - 1741. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Kunnumakkara, P. Diagaradjane, S. Guha, A. Deorukhkar, S. Shentu, B. B. Aggarwal, and S. Krishnan Curcumin Sensitizes Human Colorectal Cancer Xenografts in Nude Mice to {gamma}-Radiation by Targeting Nuclear Factor-{kappa}B-Regulated Gene Products Clin. Cancer Res., April 1, 2008; 14(7): 2128 - 2136. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Timke, H. Zieher, A. Roth, K. Hauser, K. E. Lipson, K. J. Weber, J. Debus, A. Abdollahi, and P. E. Huber Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor Therapy Clin. Cancer Res., April 1, 2008; 14(7): 2210 - 2219. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Manegold, C. Paringer, U. Kulka, K. Krimmel, M. E. Eichhorn, R. Wilkowski, K.-W. Jauch, M. Guba, and C. J. Bruns Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer Clin. Cancer Res., February 1, 2008; 14(3): 892 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. X. Cai, L. Y. Tse, C. Leung, P. K.H. Tam, R. Xu, and M. H. Sham Suppression of Lung Tumor Growth and Metastasis in Mice by Adeno-Associated Virus-Mediated Expression of Vasostatin Clin. Cancer Res., February 1, 2008; 14(3): 939 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Klopp, E. L. Spaeth, J. L. Dembinski, W. A. Woodward, A. Munshi, R. E. Meyn, J. D. Cox, M. Andreeff, and F. C. Marini Tumor Irradiation Increases the Recruitment of Circulating Mesenchymal Stem Cells into the Tumor Microenvironment Cancer Res., December 15, 2007; 67(24): 11687 - 11695. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Burger, M. W. Sill, B. J. Monk, B. E. Greer, and J. I. Sorosky Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., November 20, 2007; 25(33): 5165 - 5171. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Slongo, B. Molena, A. M. Brunati, M. Frasson, M. Gardiman, M. Carli, G. Perilongo, A. Rosolen, and M. Onisto Functional VEGF and VEGF receptors are expressed in human medulloblastomas Neuro-oncol, October 1, 2007; 9(4): 384 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ekman, M. Bergqvist, C.-H. Heldin, and J. Lennartsson Activation of Growth Factor Receptors in Esophageal Cancer Implications for Therapy Oncologist, October 1, 2007; 12(10): 1165 - 1177. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Duda, R. K. Jain, and C. G. Willett Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers J. Clin. Oncol., September 10, 2007; 25(26): 4033 - 4042. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Allen, S. Duffy, T. Teknos, M. Islam, Z. Chen, P. S. Albert, G. Wolf, and C. Van Waes Nuclear Factor-{kappa}B-Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma Clin. Cancer Res., June 1, 2007; 13(11): 3182 - 3190. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P.M. Dings, M. Loren, H. Heun, E. McNiel, A. W. Griffioen, K. H. Mayo, and R. J. Griffin Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization Clin. Cancer Res., June 1, 2007; 13(11): 3395 - 3402. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Cuneo, T. Tu, L. Geng, A. Fu, D. E. Hallahan, and C. D. Willey HIV Protease Inhibitors Enhance the Efficacy of Irradiation Cancer Res., May 15, 2007; 67(10): 4886 - 4893. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ogawa, Y. Boucher, S. Kashiwagi, D. Fukumura, D. Chen, and L. E. Gerweck Influence of Tumor Cell and Stroma Sensitivity on Tumor Response to Radiation Cancer Res., May 1, 2007; 67(9): 4016 - 4021. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Senan and E. F. Smit Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy Oncologist, April 1, 2007; 12(4): 465 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. H. Rad, H. Le Buanec, S. Paturance, P. Larcier, P. Genne, B. Ryffel, A. Bensussan, B. Bizzini, R. C. Gallo, D. Zagury, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases PNAS, February 20, 2007; 104(8): 2837 - 2842. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Williams, B. A. Telfer, A. M. Shannon, M. Babur, I. J. Stratford, and S. R. Wedge Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit Mol. Cancer Ther., February 1, 2007; 6(2): 599 - 606. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Anai, S. Goodison, K. Shiverick, Y. Hirao, B. D. Brown, and C. J. Rosser Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts Mol. Cancer Ther., January 1, 2007; 6(1): 101 - 111. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cao, J. M. Albert, L. Geng, P. S. Ivy, A. Sandler, D. H. Johnson, and B. Lu Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor AZD2171 and Fractionated Radiotherapy in Mouse Models of Lung Cancer Cancer Res., December 1, 2006; 66(23): 11409 - 11415. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pore, A. K. Gupta, G. J. Cerniglia, Z. Jiang, E. J. Bernhard, S. M. Evans, C. J. Koch, S. M. Hahn, and A. Maity Nelfinavir Down-regulates Hypoxia-Inducible Factor 1{alpha} and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy. Cancer Res., September 15, 2006; 66(18): 9252 - 9259. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Crane, L. M. Ellis, J. L. Abbruzzese, C. Amos, H. Q. Xiong, L. Ho, D. B. Evans, E. P. Tamm, C. Ng, P. W.T. Pisters, et al. Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer J. Clin. Oncol., March 1, 2006; 24(7): 1145 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Khan, F. Mamou, M. J. Schipper, K. S. May, A. Kwitny, A. Warnat, B. Bolton, B. M. Nair, M. S. T. Kariapper, M. Miller, et al. Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, March 1, 2006; 132(3): 333 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kaliski, L. Maggiorella, K. A. Cengel, D. Mathe, V. Rouffiac, P. Opolon, N. Lassau, J. Bourhis, and E. Deutsch Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion Mol. Cancer Ther., November 1, 2005; 4(11): 1717 - 1728. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Weichselbaum Bugging the intestinal response to radiation PNAS, September 20, 2005; 102(38): 13363 - 13364. [Full Text] [PDF] |
||||
![]() |
S. R. Perri, J. Nalbantoglu, B. Annabi, Z. Koty, L. Lejeune, M. Francois, M. R. Di Falco, R. Beliveau, and J. Galipeau Plasminogen Kringle 5-Engineered Glioma Cells Block Migration of Tumor-Associated Macrophages and Suppress Tumor Vascularization and Progression Cancer Res., September 15, 2005; 65(18): 8359 - 8365. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Crawford and J. I. Gordon From The Cover: Microbial regulation of intestinal radiosensitivity PNAS, September 13, 2005; 102(37): 13254 - 13259. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Vokes Optimal Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5853 - 5855. [Full Text] [PDF] |
||||
![]() |
A. Abdollahi, D. W. Griggs, H. Zieher, A. Roth, K. E. Lipson, R. Saffrich, H.-J. Grone, D. E. Hallahan, R. A. Reisfeld, J. Debus, et al. Inhibition of {alpha}v{beta}3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy Clin. Cancer Res., September 1, 2005; 11(17): 6270 - 6279. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. P. Tew, D. P. Kelsen, and D. H. Ilson Targeted Therapies for Esophageal Cancer Oncologist, September 1, 2005; 10(8): 590 - 601. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zips, W. Eicheler, P. Geyer, F. Hessel, A. Dorfler, H. D. Thames, M. Haberey, and M. Baumann Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition Cancer Res., June 15, 2005; 65(12): 5374 - 5379. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Herbst, A. Onn, and A. Sandler Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications J. Clin. Oncol., May 10, 2005; 23(14): 3243 - 3256. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Huber, M. Bischof, J. Jenne, S. Heiland, P. Peschke, R. Saffrich, H.-J. Grone, J. Debus, K. E. Lipson, and A. Abdollahi Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy Cancer Res., May 1, 2005; 65(9): 3643 - 3655. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Gupta and J Zhang Angiogenesis: a curse or cure? Postgrad. Med. J., April 1, 2005; 81(954): 236 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Anderson, R. T. Libby, D. B. Gould, R. S. Smith, and S. W. M. John High-dose radiation with bone marrow transfer prevents neurodegeneration in an inherited glaucoma PNAS, March 22, 2005; 102(12): 4566 - 4571. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions J. Clin. Oncol., February 20, 2005; 23(6): 1295 - 1311. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-P. Gerber and N. Ferrara Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies Cancer Res., February 1, 2005; 65(3): 671 - 680. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ansiaux, C. Baudelet, B. F. Jordan, N. Beghein, P. Sonveaux, J. De Wever, P. Martinive, V. Gregoire, O. Feron, and B. Gallez Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment Clin. Cancer Res., January 15, 2005; 11(2): 743 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Williams, B. A. Telfer, S. Brave, J. Kendrew, L. Whittaker, I. J. Stratford, and S. R. Wedge ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy: Schedule-Dependent Enhancement of Antitumor Activity Clin. Cancer Res., December 15, 2004; 10(24): 8587 - 8593. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kobayashi, K. Reijnders, S. English, A. T. Yordanov, D. E. Milenic, A. L. Sowers, D. Citrin, M. C. Krishna, T. A. Waldmann, J. B. Mitchell, et al. Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation Clin. Cancer Res., November 15, 2004; 10(22): 7712 - 7720. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kumar, A. I. Miller, and P. J. Polverini p38 MAPK Mediates {gamma}-Irradiation-induced Endothelial Cell Apoptosis, and Vascular Endothelial Growth Factor Protects Endothelial Cells through the Phosphoinositide 3-Kinase-Akt-Bcl-2 Pathway J. Biol. Chem., October 8, 2004; 279(41): 43352 - 43360. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Fenton, S. F. Paoni, and I. Ding Pathophysiological Effects of Vascular Endothelial Growth Factor Receptor-2-Blocking Antibody plus Fractionated Radiotherapy on Murine Mammary Tumors Cancer Res., August 15, 2004; 64(16): 5712 - 5719. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zingg, O. Riesterer, D. Fabbro, C. Glanzmann, S. Bodis, and M. Pruschy Differential Activation of the Phosphatidylinositol 3'-Kinase/Akt Survival Pathway by Ionizing Radiation in Tumor and Primary Endothelial Cells Cancer Res., August 1, 2004; 64(15): 5398 - 5406. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Geng, J. Tan, E. Himmelfarb, A. Schueneman, K. Niermann, A. Fu, K. Cuneo, E. A. Kesicki, J. Treiberg, J. S. Hayflick, et al. A Specific Antagonist of the p110{delta} Catalytic Component of Phosphatidylinositol 3'-Kinase, IC486068, Enhances Radiation-Induced Tumor Vascular Destruction Cancer Res., July 15, 2004; 64(14): 4893 - 4899. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Kulke, R. D. Odze, J. D. Mueller, H. Wang, M. Redston, and M. M. Bertagnolli Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1579 - 1586. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. X. Chen Expanding the Clinical Development of Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 27 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Kim, Y. B. Kim, N. H. Cho, H.-C. Chung, H. R. Pyo, J. D. Lee, T. K. Park, W. S. Koom, M. Chun, and C. O. Suh Synchronous Coexpression of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in Carcinomas of the Uterine Cervix: A Potential Predictor of Poor Survival Clin. Cancer Res., February 15, 2004; 10(4): 1366 - 1374. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W. Chan, M. A. Moses, E. Goley, M. Sproull, T. Muanza, C. N. Coleman, W. D. Figg, P. S. Albert, C. Menard, and K. Camphausen Urinary VEGF and MMP Levels As Predictive Markers of 1-Year Progression-Free Survival in Cancer Patients Treated With Radiation Therapy: A Longitudinal Study of Protein Kinetics Throughout Tumor Progression and Therapy J. Clin. Oncol., February 1, 2004; 22(3): 499 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kolesnick and Z. Fuks Response to Comments on "Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis" Science, December 12, 2003; 302(5652): 1894e - 1894e. [Full Text] [PDF] |
||||
![]() |
H. Choy and L. Milas Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance? J Natl Cancer Inst, October 1, 2003; 95(19): 1440 - 1452. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Denis, S. Colas, L. Chami, P. Louisot, O. le Floch, F. Tranquart, and P. Bougnoux Changes in Tumor Vascularization after Irradiation, Anthracyclin, or Antiangiogenic Treatment in Nitrosomethyl Ureas-Induced Rat Mammary Tumors Clin. Cancer Res., October 1, 2003; 9(12): 4546 - 4552. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Lev, M. Ruiz, L. Mills, E. C. McGary, J. E. Price, and M. Bar-Eli Dacarbazine Causes Transcriptional Up-Regulation of Interleukin 8 and Vascular Endothelial Growth Factor in Melanoma Cells: A Possible Escape Mechanism from Chemotherapy Mol. Cancer Ther., August 1, 2003; 2(8): 753 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Schueneman, E. Himmelfarb, L. Geng, J. Tan, E. Donnelly, D. Mendel, G. McMahon, and D. E. Hallahan SU11248 Maintenance Therapy Prevents Tumor Regrowth after Fractionated Irradiation of Murine Tumor Models Cancer Res., July 15, 2003; 63(14): 4009 - 4016. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Rofstad, K. Henriksen, K. Galappathi, and B. Mathiesen Antiangiogenic Treatment with Thrombospondin-1 Enhances Primary Tumor Radiation Response and Prevents Growth of Dormant Pulmonary Micrometastases after Curative Radiation Therapy in Human Melanoma Xenografts Cancer Res., July 15, 2003; 63(14): 4055 - 4061. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Abdollahi, K. E. Lipson, X. Han, R. Krempien, T. Trinh, K. J. Weber, P. Hahnfeldt, L. Hlatky, J. Debus, A. R. Howlett, et al. SU5416 and SU6668 Attenuate the Angiogenic Effects of Radiation-induced Tumor Cell Growth Factor Production and Amplify the Direct Anti-endothelial Action of Radiation in Vitro Cancer Res., July 1, 2003; 63(13): 3755 - 3763. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cox, S. D. Merajver, S. Yoo, R. D. Dick, G. J. Brewer, J. S.-J. Lee, and T. N. Teknos Inhibition of the Growth of Squamous Cell Carcinoma by Tetrathiomolybdate-Induced Copper Suppression in a Murine Model Arch Otolaryngol Head Neck Surg, July 1, 2003; 129(7): 781 - 785. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Wachsberger, R. Burd, and A. P. Dicker Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Roca, L. Primo, D. Valdembri, A. Cividalli, P. Declerck, P. Carmeliet, P. Gabriele, and F. Bussolino Hyperthermia Inhibits Angiogenesis by a Plasminogen Activator Inhibitor 1-dependent Mechanism Cancer Res., April 1, 2003; 63(7): 1500 - 1507. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sonveaux, A. Brouet, X. Havaux, V. Gregoire, C. Dessy, J.-L. Balligand, and O. Feron Irradiation-induced Angiogenesis through the Up-Regulation of the Nitric Oxide Pathway: Implications for Tumor Radiotherapy Cancer Res., March 1, 2003; 63(5): 1012 - 1019. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Gorski, H. J. Mauceri, R. M. Salloum, A. Halpern, S. Seetharam, and R. R. Weichselbaum Prolonged Treatment with Angiostatin Reduces Metastatic Burden during Radiation Therapy Cancer Res., January 15, 2003; 63(2): 308 - 311. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Takano, K. Tsuboi, A. Matsumura, and T. Nose Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: Effects on tumor growth and angiogenesis in human glioblastoma xenografts Neuro-oncol, January 1, 2003; 5(1): 1 - 7. [Abstract] [PDF] |
||||
![]() |
J. S. Eshleman, B. L. Carlson, A. C. Mladek, B. D. Kastner, K. L. Shide, and J. N. Sarkaria Inhibition of the Mammalian Target of Rapamycin Sensitizes U87 Xenografts to Fractionated Radiation Therapy Cancer Res., December 15, 2002; 62(24): 7291 - 7297. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. F. Dvorak Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Scappaticci Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Edwards, L. Geng, J. Tan, H. Onishko, E. Donnelly, and D. E. Hallahan Phosphatidylinositol 3-Kinase/Akt Signaling in the Response of Vascular Endothelium to Ionizing Radiation Cancer Res., August 15, 2002; 62(16): 4671 - 4677. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Burke, S. J. DeNardo, L. A. Miers, K. R. Lamborn, S. Matzku, and G. L. DeNardo Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts Cancer Res., August 1, 2002; 62(15): 4263 - 4272. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Morgan, J. G. Gross, C. N. Pagel, J. R. Beauchamp, A. Fassati, A. J. Thrasher, J. P. Di Santo, I. B. Fisher, X. Shiwen, D. J. Abraham, et al. Myogenic cell proliferation and generation of a reversible tumorigenic phenotype are triggered by preirradiation of the recipient site J. Cell Biol., May 13, 2002; 157(4): 693 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ganss, E. Ryschich, E. Klar, B. Arnold, and G. J. Hammerling Combination of T-Cell Therapy and Trigger of Inflammation Induces Remodeling of the Vasculature and Tumor Eradication Cancer Res., March 1, 2002; 62(5): 1462 - 1470. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Griffin, B. W. Williams, R. Wild, J. M. Cherrington, H. Park, and C. W. Song Simultaneous Inhibition of the Receptor Kinase Activity of Vascular Endothelial, Fibroblast, and Platelet-derived Growth Factors Suppresses Tumor Growth and Enhances Tumor Radiation Response Cancer Res., March 1, 2002; 62(6): 1702 - 1706. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Franco, I. Segura, H. H. Riese, and M. A. Blasco Decreased B16F10 Melanoma Growth and Impaired Vascularization in Telomerase-deficient Mice with Critically Short Telomeres Cancer Res., January 1, 2002; 62(2): 552 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, K. Simopoulos, J. Pastorek, C. C. Wykoff, K. C. Gatter, and A. L. Harris Hypoxia-regulated Carbonic Anhydrase-9 (CA9) Relates to Poor Vascularization and Resistance of Squamous Cell Head and Neck Cancer to Chemoradiotherapy Clin. Cancer Res., November 1, 2001; 7(11): 3399 - 3403. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Milosevic, A. Fyles, D. Hedley, M. Pintilie, W. Levin, L. Manchul, and R. Hill Interstitial Fluid Pressure Predicts Survival in Patients with Cervix Cancer Independent of Clinical Prognostic Factors and Tumor Oxygen Measurements Cancer Res., September 1, 2001; 61(17): 6400 - 6405. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, T. DeWeese, J. Dilley, Y. Zhang, Y. Li, N. Ramesh, J. Lee, R. Pennathur-Das, J. Radzyminski, J. Wypych, et al. CV706, a Prostate Cancer-specific Adenovirus Variant, in Combination with Radiotherapy Produces Synergistic Antitumor Efficacy without Increasing Toxicity Cancer Res., July 1, 2001; 61(14): 5453 - 5460. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kong, R. D. Braun, and M. W. Dewhirst Characterization of the Effect of Hyperthermia on Nanoparticle Extravasation from Tumor Vasculature Cancer Res., April 1, 2001; 61(7): 3027 - 3032. [Abstract] [Full Text] |
||||
![]() |
K. Camphausen, M. A. Moses, W.-D. Beecken, M. K. Khan, J. Folkman, and M. S. OReilly Radiation Therapy to a Primary Tumor Accelerates Metastatic Growth in Mice Cancer Res., March 1, 2001; 61(5): 2207 - 2211. [Abstract] [Full Text] |
||||
![]() |
L. Geng, E. Donnelly, G. McMahon, P. C. Lin, E. Sierra-Rivera, H. Oshinka, and D. E. Hallahan Inhibition of Vascular Endothelial Growth Factor Receptor Signaling Leads to Reversal of Tumor Resistance to Radiotherapy Cancer Res., March 1, 2001; 61(6): 2413 - 2419. [Abstract] [Full Text] |
||||
![]() |
S. V. Kozin, Y. Boucher, D. J. Hicklin, P. Bohlen, R. K. Jain, and H. D. Suit Vascular Endothelial Growth Factor Receptor-2-blocking Antibody Potentiates Radiation-induced Long-Term Control of Human Tumor Xenografts Cancer Res., January 1, 2001; 61(1): 39 - 44. [Abstract] [Full Text] |
||||
![]() |
C.-G. Lee, M. Heijn, E. di Tomaso, G. Griffon-Etienne, M. Ancukiewicz, C. Koike, K. R. Park, N. Ferrara, R. K. Jain, H. D. Suit, et al. Anti-Vascular Endothelial Growth Factor Treatment Augments Tumor Radiation Response under Normoxic or Hypoxic Conditions Cancer Res., October 1, 2000; 60(19): 5565 - 5570. [Abstract] [Full Text] |
||||
![]() |
A. Ferrario, K. F. von Tiehl, N. Rucker, M. A. Schwarz, P. S. Gill, and C. J. Gomer Antiangiogenic Treatment Enhances Photodynamic Therapy Responsiveness in a Mouse Mammary Carcinoma Cancer Res., August 1, 2000; 60(15): 4066 - 4069. [Abstract] [Full Text] |
||||
![]() |
N. Hansen-Algenstaedt, B. R. Stoll, T. P. Padera, D. E. J. G. J. Dolmans, D. J. Hicklin, D. Fukumura, and R. K. Jain Tumor Oxygenation in Hormone-Dependent Tumors During Vascular Endothelial Growth Factor Receptor-2 Blockade, Hormone Ablation, and Chemotherapy Cancer Res., August 1, 2000; 60(16): 4556 - 4560. [Abstract] [Full Text] |
||||
![]() |
C. Li, S. Ke, Q.-P. Wu, W. Tansey, N. Hunter, L. M. Buchmiller, L. Milas, C. Charnsangavej, and S. Wallace Tumor Irradiation Enhances the Tumor-specific Distribution of Poly(L-glutamic acid)-conjugated Paclitaxel and Its Antitumor Efficacy Clin. Cancer Res., July 1, 2000; 6(7): 2829 - 2834. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |